Frankfurt
08.09.25 | 15:29
1,236 Euro
-0,80 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 244 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 300 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07. | Advicenne Reports its H1 2025 Sales | 294 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07. | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 702 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 285 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 30.06. | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 350 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
| 29.04. | ADVICENNE: Advicenne met à disposition son Document d'Enregistrement Universel 2024 | 2 | Euronext | ||
| 29.04. | Advicenne 2024 Universal Registration Document Made Available | 252 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 505 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 453 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 430 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 487 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 205 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 01.10.24 | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 441 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| 18.09.24 | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 486 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,950 | -1,37 % | Lohnt hier der Einstieg? NetraMark, Novartis, Pfizer | Aufgrund der globalen Nachfrage nach Gesundheitsdienstleistungen und technologischen Erneuerungen kann eine Investition in den Gesundheitssektor besonders lukrativ sein. Der demografische Wandel in... ► Artikel lesen | |
| ABBVIE | 177,60 | -2,09 % | Deals im Milliarden-Markt für Psychedelika: AbbVie, Atai Life Sciences, Neural Therapeutics | ||
| HAEMATO | 10,700 | +3,88 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
| HALEON | 4,146 | -1,85 % | Haleon PLC - Director/PDMR Shareholding | ||
| ACHIEVE LIFE SCIENCES | 2,400 | -0,83 % | Achieve Life Sciences Announces FDA Acceptance of Cytisinicline NDA (POSITIVE) | ||
| LIGAND PHARMACEUTICALS | 143,00 | +0,70 % | Oppenheimer raises Ligand Pharma stock price target to $190 on lower WACC | ||
| ROYALTY PHARMA | 30,160 | -2,05 % | Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900... ► Artikel lesen | |
| EISAI | 31,300 | +3,40 % | Eisai-Aktie gewinnt 4,07 Prozent (27,33 €) | Am Aktienmarkt liegt die Eisai-Aktie derzeit im Plus. Zuletzt zahlten Investoren für das Papier 27,33 Euro. Freuen können sich gegenwärtig die Aktionäre von Eisai: Die Aktie weist zur Stunde einen Preisanstieg... ► Artikel lesen | |
| DR REDDYS | 12,100 | 0,00 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| TG THERAPEUTICS | 26,605 | -3,24 % | TG Therapeutics, Inc.: TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment | NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy)... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 89,40 | -1,54 % | Merck taps bond market to fund $10 billion Verona Pharma acquisition - Bloomberg | ||
| BETTERLIFE PHARMA | 0,046 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders | VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on... ► Artikel lesen | |
| ENTOURAGE HEALTH | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.04.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.04.2025ISIN NameCA2938611001 ENTOURAGE... ► Artikel lesen | |
| KYOWA KIRIN | 14,800 | -1,99 % | Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress | PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational... ► Artikel lesen | |
| IGC PHARMA | 0,360 | -2,70 % | IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada | POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.